Aim To evaluate if the prognosis was different between coronary bifurcation lesions and non-coronary bifurcation lesions when treated with drug-eluting stents. Methods For this retrospective study,1877 patients were enrolled.568 cases were coronary bifurcation lesions and 1309 cases were non-coronary bifurcation lesions.All of the patients were treated with Excel stents.Clinical follow-up at 6 months,12 months and 18 months were completed in all patients to evaluate the safety and efficacy. Results There were no differences on the rate of death(including cardiogenic and non-cardiogenic),non-fatal myocardial infarction and major adverse cardiac events(MACE) at 6 months,12 months and 18 months between the two groups.There were no differences on the rate of target lesion revascularization(TLR) at 6 months and 12 months.The rate of TLR was higher at 18 months in the coronary bifurcation lesions group. Conclusion It was safe and efficient to treat coronary bifurcation lesions with Excel stent.